Kim Jun-Kyum, Jeon Hee-Young, Kim Hyunggee
Department of Biotechnology, School of Life Sciences and Biotechnology, Korea University, 5-ga, Anam-dong, Seongbuk-gu, Life Science West Building 207, Seoul, 136-713, Republic of Korea.
Arch Pharm Res. 2015 Mar;38(3):389-401. doi: 10.1007/s12272-014-0531-1. Epub 2014 Dec 13.
Chemo-resistance and radio-resistance are a major cause of recurrence and progression of many cancers, regardless of improvements in therapies. Since cancer stem cells (CSCs) were identified as a rare population with the abilities of self-renewal; tumor initiation; aberrant differentiation, which contributes to tumor heterogeneity; and resistance to anticancer therapeutics, they have been considered a major cause of tumor recurrence post-therapy and a primary therapeutic target in relapse prevention. A number of studies have demonstrated the mechanisms underlying chemo-resistance and radio-resistance of CSCs. In this review, we describe intrinsic and extrinsic factors underlying CSC chemo-resistance and radio-resistance. The intrinsic factors regulate CSC signaling pathways involved in stem cell signaling, anti-apoptotic pathways, ABC transporter expression, and DNA damage repair systems. The extrinsic factors include the resistance mechanisms resulting from the interactions between CSCs and the microenvironment composed of vessels, fibroblasts, immune cells, extracellular matrix, and diverse soluble factors. Furthermore, we introduce diverse therapeutic agents used in experimental or clinical trials to target CSCs. Understanding how CSCs acquire resistance to anticancer therapeutics will give us opportunity to develop improved therapeutic approaches.
化疗耐药和放疗耐药是许多癌症复发和进展的主要原因,无论治疗方法有何改进。自从癌症干细胞(CSCs)被鉴定为具有自我更新能力的稀有细胞群体以来;肿瘤起始;异常分化,这导致肿瘤异质性;以及对抗癌治疗的耐药性,它们一直被认为是治疗后肿瘤复发的主要原因和预防复发的主要治疗靶点。许多研究已经证明了癌症干细胞化疗耐药和放疗耐药的潜在机制。在这篇综述中,我们描述了癌症干细胞化疗耐药和放疗耐药的内在和外在因素。内在因素调节参与干细胞信号传导、抗凋亡途径、ABC转运蛋白表达和DNA损伤修复系统的癌症干细胞信号通路。外在因素包括癌症干细胞与由血管、成纤维细胞、免疫细胞、细胞外基质和各种可溶性因子组成的微环境之间相互作用产生的耐药机制。此外,我们介绍了用于靶向癌症干细胞的实验或临床试验中的各种治疗药物。了解癌症干细胞如何获得对抗癌治疗的耐药性将为我们提供开发改进治疗方法的机会。